A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ABVC BIOPHARMA, INC.
ABVC
$23M
Mkt Cap
$1.15
-4.17%
ABVC BIOPHARMA, INC. (ABVC) has a 5-year average return on invested capital (ROIC) of -133.7%. This is below average and may indicate limited pricing power.
ABVC BIOPHARMA, INC. (ABVC) has a market capitalization of $23M. It is classified as a small-cap stock.
ABVC BIOPHARMA, INC. (ABVC) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.03%.
ABVC BIOPHARMA, INC. (ABVC) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ABVC BIOPHARMA, INC. (ABVC) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ABVC BIOPHARMA, INC. (ABVC) has a debt-to-equity ratio of 0.26. This indicates a conservatively financed balance sheet.
ABVC BIOPHARMA, INC. (ABVC) reported earnings per share (EPS) of $-0.39 in its most recent fiscal year.
Industry Overview The biotechnology industry focuses on developing breakthrough products and technologies to combat various diseases through efficient industrial manufacturing. Biotechnology is an important business sector in the world’s economies and is vital to human health. Companies engaged in biotechnology generally require large amounts of capital investment for their research & development activities. Developing and commercializing a new drug or medical device may take up to tens of years. ABVC (“we” or the “Company”) is an early-stage biotechnology company with a pipeline of seven new drugs and one medical device under development, all of which are licensed from related parties of the Company. Our Mission We devote our resources to building a sophisticated biotech company and becoming a pioneer in the biopharmaceutical industry. Dr. Uttam Patil, our Chief Executive Officer, and Dr.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -7.9M | -7.9M | 5.3M | -7.8M | -16M | -13M |
| EPS | $-0.39 | $-0.39 | $0.38 | $-1.80 | $-20.76 | $-2.04 |
| Free Cash Flow | -3.0M | -3.0M | 1.8M | -4.2M | -7.5M | -7.6M |
| ROIC | -42.3% | -42.5% | -200.8% | -144.7% | -199.3% | -148.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.26 | 0.26 | 1.21 | 1.47 | 0.99 | 0.38 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -7.2M | -7.2M | -4.7M | -6.8M | -15M | -12M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -71.2% | -128.2% | 378.3% | -334.8% | -275.0% | -209.1% |
| Shares Outstanding | 20M | 20M | 14M | 4M | 1M | 6M |
| Metric | 2016 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | 10M | 989K | 1.0M | 550K | 1.0M | 2.7M | 1.1M | 179K | 121K | 121K |
| SG&A | N/A | N/A | N/A | 4.5M | 1.6M | 3.1M | 4.3M | 5.7M | 6.1M | 5.4M | 2.3M | 2.9M | 2.9M |
| EBIT | -177K | N/A | -32K | -11M | -2.8M | -3.5M | -8.5M | -12M | -15M | -6.8M | -4.7M | -7.2M | -7.2M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -236K | N/A | -32K | -11M | -6.1M | -3.9M | -9.8M | -13M | -16M | -7.8M | 5.3M | -7.9M | -7.9M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 2.2M | 0 | 961K | 741K | 110K | 0 | 0 | 11K | 11K |
| Returns on Capital | |||||||||||||
| ROIC | -60.4% | N/A | -2.5% | N/M | -37.0% | -65.3% | -132.6% | -148.4% | -199.3% | -144.7% | N/M | -42.5% | -42.3% |
| ROE | 13.4% | N/A | -7.0% | N/A | 163.6% | 135.4% | -284.8% | -209.1% | -275.0% | -334.8% | 378.3% | -128.2% | -71.2% |
| ROA | -88.5% | N/A | -6.0% | -6206.8% | -141.3% | -61.1% | -105.7% | -101.5% | -141.1% | -89.7% | 68.6% | -55.3% | -37.5% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -38K | 1K | 3K | -3.5M | -901K | -3.1M | -4.6M | -7.6M | -7.4M | -4.2M | 1.8M | -3.0M | -3.0M |
| Free Cash Flow | -38K | 1K | 3K | -3.5M | -901K | -3.1M | -4.6M | -7.6M | -7.5M | -4.2M | 1.8M | -3.0M | -3.0M |
| Owner Earnings | -62K | 1K | -30M | -4.8M | -973K | -3.2M | -8.7M | -13M | -14M | -4.4M | -996K | -7.2M | -7.2M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18K | 120K | 21K | 0 | 0 | 0 |
| Maint. CapEx | 24K | 0 | 0 | 0 | 44K | 55K | 37K | 12K | 24K | 29K | 32K | 25K | 25K |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6K | 96K | 0 | N/A | N/A | 0 |
| D&A | 24K | 0 | 0 | 0 | 44K | 55K | 37K | 12K | 24K | 29K | 32K | 25K | 25K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7K | 7K | 7K |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% |
| Stock-Based Comp | N/A | 0 | 30M | 1.3M | 29K | 22K | 4.1M | 5.3M | 7.0M | 186K | 2.8M | 4.1M | 4.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 307K | 0 | 1.0M | 126K | 120K | 120K |
| Balance Sheet | |||||||||||||
| Net Debt | 0 | 14K | -1.6M | N/A | 2.1M | 4.3M | 1.6M | -2.6M | 2.9M | 2.1M | 1.2M | 2.2M | 2.2M |
| Cash & Equiv. | 0 | 0 | 1.6M | 174K | 227K | 144K | 4.3M | 5.8M | 85K | 60K | 248K | 681K | 681K |
| Long-Term Debt | 0 | 7K | 7K | N/A | 899K | 1.9M | 2.5M | 236K | 0 | 0 | N/A | N/A | 2.9M |
| Debt/Equity | 0.00 | 0.45 | 0.01 | -1.03 | -0.41 | -29.66 | 1.72 | 0.38 | 0.99 | 1.47 | 1.21 | 0.26 | 0.26 |
| Interest Coverage | -3.6 | N/A | N/A | -1081.3 | -6.0 | -7.2 | -21.0 | -51.5 | -51.4 | -5.2 | -7283.7 | -17.2 | -17.2 |
| Equity | -1.9M | 31K | 897K | -6.4M | -5.7M | -151K | 3.4M | 8.8M | 3.1M | 1.6M | 1.2M | 11M | 11M |
| Total Assets | 232K | 65K | 1.0M | 177K | 5.9M | 6.9M | 12M | 14M | 9.6M | 7.8M | 7.5M | 21M | 21M |
| Total Liabilities | 2.1M | 34K | 369K | 6.6M | 11M | 7.1M | 8.9M | 4.8M | 6.3M | 6.5M | 6.8M | 7.8M | 7.8M |
| Intangibles | 193K | 65K | 65K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -31M | -23K | -316K | -11M | -12M | -16M | -26M | -38M | -55M | -64M | -69M | -77M | -77M |
| Working Capital | -2.1M | -33K | N/A | N/A | -10M | -5.9M | 1.3M | 4.0M | -2.6M | -4.4M | -4.4M | -3.7M | -3.7M |
| Current Assets | 2K | 0 | 999K | 174K | 566K | 878K | 6.2M | 7.7M | 3.0M | 1.7M | 2.2M | 2.5M | 2.5M |
| Current Liabilities | 2.1M | 34K | N/A | N/A | 11M | 6.8M | 4.8M | 3.7M | 5.5M | 6.1M | 6.6M | 6.2M | 6.2M |
| Per Share Data | |||||||||||||
| EPS | -0.07 | -0.16 | -0.16 | -10.80 | -24.49 | -0.84 | -2.00 | -2.04 | -20.76 | -1.80 | 0.38 | -0.39 | -0.39 |
| Owner EPS | -0.02 | 0.00 | -148.68 | -4.68 | -3.93 | -0.69 | -1.79 | -2.05 | -18.28 | -1.02 | -0.07 | -0.35 | -0.35 |
| Book Value | -0.55 | 0.01 | 4.45 | -6.26 | -22.85 | -0.03 | 0.70 | 1.41 | 3.92 | 0.36 | 0.09 | 0.55 | 0.55 |
| Cash Flow/Share | -0.01 | 0.00 | 0.02 | -3.41 | -3.64 | -0.67 | -0.93 | -1.21 | -9.35 | -0.97 | 0.13 | -0.15 | -0.39 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 3.4M | 3.4M | 0.2M | 1.0M | 0.2M | 4.7M | 4.9M | 6.3M | 0.8M | 4.3M | 13.9M | 20.3M | 20.3M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.5 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | 299.0 | 104.8 | 6.4 | 12.7 | 12.1 | 4.4 | 2.1 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -0.0% | 0.0% | N/A | -0.0% | -0.0% | -0.3% | -0.4% | -0.8% | -37.7% | -21.3% | 12.2% | -6.1% | -12.8% |
| Market Cap | 156.5B | 125.2B | N/A | 66.0B | 3.2B | 965M | 1.0B | 926M | 20M | 20M | 15M | 49M | 23M |
| Avg. Price | 5,558.46 | 3,239.65 | 1,341.02 | 605.55 | 334.98 | 156.46 | 34.95 | 41.03 | 15.95 | 4.36 | 0.90 | 1.94 | 1.15 |
| Year-End Price | 2,866.24 | 2,292.99 | 1,433.12 | 360.00 | 270.00 | 51.50 | 52.50 | 36.80 | 6.30 | 1.25 | 0.58 | 2.43 | 1.15 |
ABVC BIOPHARMA, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
ABVC BIOPHARMA, INC. (ABVC) has a return on equity (ROE) of -128.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for ABVC BIOPHARMA, INC. (ABVC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ABVC BIOPHARMA, INC. (ABVC) has a book value per share of $0.55, based on its most recent annual SEC filing.
No recent press releases.